However, evaluation of the progression-free (PFS) and overall survival (OS) probabilities in high-risk NB patients treated with or without IL-2 did not reveal any additional treatment benefit of IL-2, while higher treatment-related toxicity was observed in the patients who additionally received IL-2 [4]. Here, IL2 is linked to neuroblastoma.